©The Author(s) 2024.
World J Gastroenterol. Mar 14, 2024; 30(10): 1346-1357
Published online Mar 14, 2024. doi: 10.3748/wjg.v30.i10.1346
Published online Mar 14, 2024. doi: 10.3748/wjg.v30.i10.1346
Table 3 Risks of new-onset metabolic dysfunction-associated fatty liver disease stratified by different categories of cumulative effects of excess high-normal alanine aminotransferase level
| Categories | Univariate, HR (95%CI) | P value | Sex-, WC-, SBP-, DBP- and BMI-adjusted1, HR (95%CI) | P value | Multivariate-adjusted2 | P value |
| Cumulative occurrences of ehALT (n = 3553) | ||||||
| 0 (101/1738) | 1.000 | 1.000 | 1.000 | |||
| 1 (82/851) | 1.672 (1.249-2.237) | 0.001 | 1.312 (0.975-1.765) | 0.073 | 1.261 (0.935-1.699) | 0.128 |
| 2 (70/512) | 2.325 (1.714-3.154) | < 0.001 | 1.495 (1.091-2.049) | 0.012 | 1.443 (1.050-1.982) | 0.024 |
| 3 (83/452) | 2.963 (2.215-3.962) | < 0.001 | 1.559 (1.142-2.128) | 0.005 | 1.551 (1.135-2.119) | 0.006 |
| P value for trend3 | < 0.001 | 0.005 | 0.005 | |||
| Equally weighted cumulative effects of ehALT (n = 3553) | ||||||
| Increase per SD4 | 1.227 (1.149-1.310) | < 0.001 | 1.090 (1.006-1.182) | 0.036 | 1.088 (1.003-1.179) | 0.041 |
| 0 (reference) | 1.000 | 1.000 | 1.000 | |||
| Q1 (0.01-3.00 U/L) | 1.541 (1.069-2.225) | 0.020 | 1.139 (0.785-1.652) | 0.493 | 1.083 (0.744-1.575) | 0.678 |
| Q2 (3.01-8.50 U/L) | 1.770 (1.261-2.485) | 0.001 | 1.329 (0.941-1.876) | 0.106 | 1.297 (0.916-1.837) | 0.916 |
| Q3 (8.51-20.50 U/L) | 2.620 (1.926-3.564) | < 0.001 | 1.671 (1.214-2.300) | 0.002 | 1.651 (1.199-2.273) | 0.002 |
| Q4 (≥ 20.51 U/L) | 2.852 (2.120-3.838) | < 0.001 | 1.578 (1.151-2.162) | 0.005 | 1.535 (1.119-2.106) | 0.008 |
| P value for trend3 | < 0.001 | 0.005 | 0.007 | |||
| Unequally weighted cumulative effects of ehALT (n = 3553) | ||||||
| Increase per SD4 | 1.231 (1.154-1.312) | < 0.001 | 1.102 (1.020-1.191) | 0.014 | 1.098 (1.017-1.185) | 0.016 |
| 0 (reference) | 1.000 | 1.000 | 1.000 | |||
| Q1 (0.01-5.00 U/L) | 1.709 (1.209-2.416) | 0.002 | 1.190 (0.835-1.697) | 0.336 | 1.114 (0.779-1.591) | 0.555 |
| Q2 (5.01-15.00 U/L) | 1.749 (1.234-2.478) | 0.002 | 1.283 (0.900-1.830) | 0.168 | 1.278 (0.895-1.826) | 0.177 |
| Q3 (15.01-40.50 U/L) | 2.319 (1.688-3.187) | < 0.001 | 1.636 (1.178-2.273) | 0.003 | 1.616 (1.162-2.246) | 0.004 |
| Q4 (≥ 40.51 U/L) | 2.996 (2.236-4.015) | < 0.001 | 1.626 (1.191-2.220) | 0.002 | 1.580 (1.155-2.162) | 0.004 |
| P value for trend3 | < 0.001 | 0.003 | 0.004 | |||
| Single ehALT occurrence (control group, n = 1969) | ||||||
| Increase per SD4 | 1.055 (0.866-1.286) | 0.594 | 1.010 (0.819-1.245) | 0.929 | 1.012 (0.811-1.262) | 0.917 |
| 0 (reference) | 1.000 | 1.000 | 1.000 | |||
| Q1 (0.01-1.50 U/L) | 0.688 (0.218-2.171) | 0.524 | 0.497 (0.150-1.528) | 0.214 | 0.557 (0.174-1.783) | 0.324 |
| Q2 (1.51-3.50 U/L) | 0.612 (0.151-2.485) | 0.492 | 0.462 (0.113-1.886) | 0.282 | 0.352 (0.085-1.462) | 0.151 |
| Q3 (3.51-8.50 U/L) | 1.250 (0.460-3.397) | 0.662 | 1.326 (0.486-3.620) | 0.582 | 1.043 (0.374-2.908) | 0.936 |
| Q4 (≥ 8.51 U/L) | 1.990 (0.808-4.898) | 0.134 | 1.688 (0.675-4.221) | 0.263 | 1.828 (0.772-4.593) | 0.199 |
| P value for trend3 | 0.142 | 0.259 | 0.264 | |||
- Citation: Chen JF, Wu ZQ, Liu HS, Yan S, Wang YX, Xing M, Song XQ, Ding SY. Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China. World J Gastroenterol 2024; 30(10): 1346-1357
- URL: https://www.wjgnet.com/1007-9327/full/v30/i10/1346.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i10.1346